Q2 Earnings Forecast for ESLA Issued By Zacks Research

Estrella Immunopharma, Inc. (NASDAQ:ESLA) – Analysts at Zacks Research issued their Q2 2026 EPS estimates for shares of Estrella Immunopharma in a report issued on Tuesday, July 14th. Zacks Research analyst D. Bautz anticipates that the company will post earnings of ($0.09) per share for the quarter. The consensus estimate for Estrella Immunopharma’s current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Estrella Immunopharma’s Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.29) EPS.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings results on Saturday, May 16th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03.

Separately, Weiss Ratings raised Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 12th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.00.

Estrella Immunopharma Stock Up 13.2%

ESLA stock opened at $0.84 on Friday. Estrella Immunopharma has a 52-week low of $0.73 and a 52-week high of $3.15. The firm has a market cap of $36.15 million, a P/E ratio of -2.47 and a beta of 0.85. The company’s 50-day simple moving average is $1.04 and its 200-day simple moving average is $1.20.

Institutional Trading of Estrella Immunopharma

A number of institutional investors and hedge funds have recently modified their holdings of ESLA. Renaissance Technologies LLC raised its position in shares of Estrella Immunopharma by 1,045.7% during the 4th quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock worth $191,000 after purchasing an additional 111,779 shares during the last quarter. Marshall Wace LLP acquired a new stake in Estrella Immunopharma in the 4th quarter worth about $88,000. XTX Topco Ltd boosted its holdings in Estrella Immunopharma by 376.9% in the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after buying an additional 39,099 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in Estrella Immunopharma during the 4th quarter worth approximately $43,000. Finally, State Street Corp increased its stake in Estrella Immunopharma by 93.5% during the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after buying an additional 20,900 shares in the last quarter. Hedge funds and other institutional investors own 0.35% of the company’s stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.